Add to Basket
Order hotline:
 |
+1 404 474 4654 |
 |
+1 888 205 9894 (TF) |
Membrane-Spanning 4-Domains, Subfamily A, Member 1 (MS4A1) antibody
| Antigen | Membrane-Spanning 4-Domains, Subfamily A, Member 1 (MS4A1) |
| Synonyms | B1, S7, Bp35, CD20, MS4A2, LEU-16, MGC3969, Cd20, Ly-44, Ms4a2, AA960661, FcRB, Fce1b, Ms4a1, Fcer1b, Fcrbeta, FCIGA, MS4A1, bp35, cd20, ms4a2, leu-16, ms4a4c, cd20-like |
| Clonality | Monoclonal (MEM-269) |
| Host |
 Alternatives Mouse |
| Reactivity |
Alternatives Human |
| Application |
Alternatives Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
|
| Catalog no. | ABIN125753 |
| Quantity | 0.1 mg (1 mg/ml) |
| Price | 260.00 $ Plus shipping costs $35.00 |
| Shipping to |
|
| Availability | Ships within 3 to 5 Business Days |
Additional Information
| Alternative name | CD20 |
| Immunogen | RAMOS human lymphoma cell line |
| Format | Purified |
| Isotype | IgM (Matching secondary antibodies) |
| Clone | MEM-269 |
| Description | CD20 is a cell surface 33-37 (depending on the degree of phosphorylation) kDanon-glycosylated surface phosphoprotein expressed on mature and most malignant B cells,but not stem cells or plasma cells (low number of the CD20 has been also detected on asubpopulation of T lymphocytes and it can be expressed on follicular dendritic cells). Itsexpression on B cells is synchronous with the expression of surface IgM. CD20 regulatestransmembrane calcium conductance (probably functioning as a component ofstore-operated calcium channel), cell cycle progression and B-cell proliferation. It isassociated with lipid rafts, but the intensity of this association depends on extracellulartriggering, employing CD20 conformational change and/or BCR (B cell antigen receptor)aggregation. After the receptor ligation, BCR and CD20 colocalize and then rapidlydissociate before BCR endocytosis, whereas CD20 remains at the cell surface. CD20serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it isexpressed at high levels on most B-cell malignancies, but does not become internalized orshed from the plasma membrane following mAb treatment. |
| Specificity | The antibody MEM-269 reacts with CD20 (Bp35), a 33-37 kDa non-glycosylated membranereceptor with four transmembrane domains, expressed on B lymphocytes (it is lost onplasma cells), follicular dendritic cells, and at low levels on peripheral blood T lymphocytes. |
Application Details
| Concentration | 1 mg/ml |
| Purity | > 95% (by SDS-PAGE) |
| Purification | Purified from hybridoma culture supernatant by hydrophobic charge inductionchromatography followed by precipitation methods. |
| Buffer | Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4 |
| Storage | Store at 2-8 o C. Do not use after expiration date stamped on vial label. Do not freeze. |
| Research Area | Cancer, Hematopoietic Progenitors, Hematopoietic Stem Cells, Adaptive Immunity, CD Antigens, Surface Receptors of Immune Cells |
| Restrictions | For Research Use only |
Alternatives
Alternatives for antigen "Membrane-Spanning 4-Domains, Subfamily A, Member 1 (MS4A1)", type "Antibodies"
